Skip to main content
Chinese regulators approve clinical trial of multiple myeloma drug
3/13/2019

China's National Medical Products Administration approved a clinical trial for CStone Pharmaceuticals' histone deacetylase 6 selective inhibitor CS3003. The drug is intended to treat multiple myeloma.

Full Story: